Objective: To determine how amyloid ␤ 42 (A␤42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of dementia.
Differential dementia diagnosis is based on clinical criteria and ancillary investigations may provide positive evidence for a specific, nosologic diagnosis. Measurements of biochemical markers in CSF are increasingly used in the diagnostic process of dementia. The sensitivity when using the combination of CSF A␤42 and total tau (t-tau) for recognition of Alzheimer disease (AD) is high. 1 However, specificity is suboptimal concerning patients with subjective memory complaints (SMC) 2 and other types of dementia. 3, 4 There are several potential explanations for the finding of abnormal markers in patients with other types of dementia. Clinical misdiagnosis or mixed pathology-which is a common finding at autopsy 4 -may explain positive markers. Alternatively, amyloid ␤ and (phosphorylated) tau play also a role in the pathogenesis of other types of dementias. Tau pathology is as well seen in frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), 5 and prion diseases. 6 Amyloid deposition or disturbance in amyloid metabolism is found in a few patients with FTLD.
The aim of the present study is to investigate how CSF A␤42, t-tau, and phosphorylated tau (p-tau) levels behave in a large sample of patients, recruited consecutively at our memory clinic. First, CSF biomarker levels are compared between patients with different types of dementia, patients with subjective memory complaints, and patients with psychiatric disorders. Second, we aim to identify the optimal combination of CSF biomarkers for the discrimination of AD from other types of dementias. For the verification of the clinical diagnosis, we use postmortem diagnosis obtained by autopsy in a subgroup of patients.
METHODS Patients.
Between October 1999 and November 2009, baseline CSF was collected from 1,672 patients from our outpatient memory clinic. CSF was obtained at a median of 2 months (interquartile range [IQR] 1-5 months) after diagnosis. From these 1,672 patients, 1,194 patients were selected: 512 patients with probable AD, 144 patients with FTLD (including patients with behavioral type frontotemporal dementia, semantic dementia, and progressive nonfluent aphasia), 52 patients with dementia with Lewy bodies (DLB), 34 patients with vascular dementia (VaD), 16 patients with CBD, 20 patients with progressive supranuclear palsy (PSP), 6 patients with Creutzfeldt-Jakob disease (CJD), 135 patients with a psychiatric disorder (PSY), and 275 patients with SMC. Patients with mild cognitive impairment (n ϭ 230), patients with possible AD (n ϭ 16), patients with a wide range of other neurologic diseases but no dementia (n ϭ 73), and patients with other unclassified types of dementia (n ϭ 21) were not included, nor were patients whose diagnosis was postponed or unclear (n ϭ 138). All patients underwent a standardized dementia assessment including medical history, informant-based history, physical and neurologic examination, laboratory tests, neuropsychological testing, EEG, and MRI of the brain. Diagnosis was made by consensus in a multidisciplinary meeting, without knowledge of CSF results, and according to clinical diagnostic criteria: National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for AD, 8 consensus criteria frontotemporal lobar degeneration for FTLD, 9 McKeith criteria for DLB, 10 National Institute of Neurological Disorders and Stroke (NINDS)-Association Internationale pour la Recherche en l'Enseignement en Neurosciences for VaD, 11 CBD according to criteria of Boeve, 12 PSP according to the NINDS-Society for Progressive Supranuclear Palsy criteria, 13 and CJD according to recent criteria. 14 Patients were defined as having a psychiatric disorder (PSY) when based on thorough investigation a neurodegenerative disease seemed unlikely, and clinically there was a suspicion of a psychiatric disorder. Those patients were subsequently referred to a psychiatrist. When clinical investigations yielded normal results (i.e., criteria for MCI not fulfilled), patients were considered to have SMC. Patients with SMC were considered as controls based on normal clinical investigations. Dementia severity was assessed using the Mini-Mental State Examination (MMSE).
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Standard protocol approvals, registrations, and patient consents. The study was approved by the ethical review board of the VU University Medical Center. Written informed consent was obtained from all subjects participating in the study. CSF analysis. CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space, using a 25-gauge needle, and collected in 10-mL polypropylene tubes. Within 2 hours, CSF samples were centrifuged at 2,100 g for 10 minutes at 4°C. A small amount of CSF was used for routine analysis. Aliquots of each sample were immediately frozen at Ϫ80°C until further analysis. CSF A␤42, t-tau, and p-tau phosphorylated at threonine 181 concentrations were determined using commercially available sandwich ELISAs (Innogenetics, Ghent, Belgium). 1 The performance of the assays was monitored with pools of surplus CSF specimens available from an earlier study. Multiple specimens with various concentrations included in 7-18 runs were used for this purpose. The interassay coefficient of variation (mean Ϯ SD) was 11.3 Ϯ 4.9% for A␤42, 9.3 Ϯ 1.5% for t-tau, and 9.4 Ϯ 2.5% for p-tau-181. 16 The 3 biomarkers were simultaneously analyzed in every CSF sample. CSF A␤42 data are missing in 4 cases, t-tau data in 13 cases, and p-tau-181 data in 6 cases.
Autopsy. In the 10-year period of CSF sampling, 17 patients underwent autopsy. The neuropathologic diagnosis from these patients was compared to the clinical diagnosis and to the antemortem CSF biomarker profile. For AD, the criteria of Braak were used modified for thin sections 17 and vascular amyloid ␤ deposits were assessed according to BrainNet Europe (BNE) instructions. 18 For FTLD, the Cairns classification was used. 19 For DLB, the Braak criteria were used 20 modified according to the BNE instructions. 21 VaD was classified according to Kalaria et al., 22 CJD according to Cali et al., 23 and PSP according to Litvan et al. 24 The neuropathologist was unaware of the CSF biomarker results.
Statistical analysis. For statistical analysis, SPSS, version
16.0, was used. As all variables, except for age, were not normally distributed, nonparametric analyses (Kruskal-Wallis followed by the Mann-Whitney U test) were used to compare groups. Post hoc, the different groups were compared with AD and SMC only. For categorical data, we used the 2 test. Correlations are estimated with the Spearman method. Patients with CJD were omitted from the statistical analyses when comparing groups, because of their small number. Logistic regression analysis with backward stepwise selection was used to estimate the simultaneous impact of the continuous variables CSF A␤42, t-tau, and p-tau on the diagnosis AD compared to controls and compared to the pooled groups of other types of dementia. SMC and PSY are pooled as controls, based on the comparability of their biomarker results. Patients with other types of dementia are collectively defined other dementias (OD). An optimal cutoff line was calculated comparing AD vs OD. Based on the cutoff line the percentage of patients with a CSF AD profile was calculated. Age, MMSE, and disease severity were compared between patients with and without a CSF AD profile. Statistical significance was set at p Ͻ 0.05.
RESULTS

Patients.
Baseline characteristics are shown in table 1. Age differed among groups, with patients with VaD, DLB, and AD being oldest, and PSY, SMC, and CBD being youngest. There are also sex differences among groups, with an overrepresentation of men in DLB and VaD.
CSF analysis. CSF levels of A␤42, t-tau, and p-tau. Median CSF levels of the 3 biomarkers by diagnostic group are shown in table 1. Table 2 summarizes the behavior of the CSF biomarkers in each diagnostic group as compared to SMC. In FTLD, (moderately) decreased levels of CSF A␤42 and (moderately) increased levels of CSF t-tau are found compared to SMC subjects, while CSF p-tau levels were normal. In DLB, CSF levels of A␤42 are slightly decreased and CSF t-tau and p-tau levels are increased. In VaD, CSF A␤42 is decreased but CSF t-tau and p-tau are normal. In CBD there is a trend toward a decreased CSF A␤42 ( p ϭ 0.06) at a normal CSF t-tau and p-tau (although the latter with remarkable overlap).
Patients with CJD exhibit an extremely high CSF t-tau, while CSF p-tau is relatively less elevated and CSF A␤42 levels are normal. In PSP and PSY, CSF levels of A␤42, t-tau, and p-tau are comparable to SMC subjects. 
Abbreviations: A␤42 ϭ amyloid ␤ 42; AD ϭ Alzheimer disease; CBD ϭ corticobasal degeneration; CJD ϭ Creutzfeldt-Jakob disease; DLB ϭ dementia with Lewy bodies; FTLD ϭ frontotemporal lobar degeneration; p-tau ϭ phosphorylated tau; PSP ϭ progressive supranuclear palsy; PSY ϭ psychiatric disorder; SMC ϭ subjective memory complaints; The CSF profile exhibits a high CSF p-tau (88 pg/mL) and t-tau (604 pg/mL), at a borderline CSF A␤42 (567 pg/mL). It should be noted that this patient was 80 years old at autopsy. In 6 out of 7 patients with clinically diagnosed AD, a CSF AD profile was found, except for patient 6, who has a CSF profile congruent with non-AD
Figure
Scatterplot of CSF amyloid ␤ 42 (A␤42) and phosphorylated tau (p-tau) in other dementias
The equation of the line for optimal separation is A␤42 ϭ 152 ϩ 8.25 ϫ p-tau (obtained from logistic regression analysis comparing Alzheimer disease with the pooled group of other dementias). CBD ϭ corticobasal degeneration; CJD ϭ Creutzfeldt-Jakob disease; DLB ϭ dementia with Lewy bodies; FTLD ϭ frontotemporal lobar degeneration; PSP ϭ progressive supranuclear palsy; VAD ϭ vascular dementia.
and a neuropathologic diagnosis of DLB. Revision of the clinical data reveals a change in diagnosis to probable PSP instead of AD. Patient 12 has an ambiguous clinical diagnosis with both FTLD and alcohol abuse, and neuropathologically hippocampal sclerosis, which fits both clinical diagnoses. CSF A␤42 is decreased in this patient (418 pg/mL), while CSF p-tau is normal (42 pg/mL), resulting in a borderline CSF AD profile. Because of the hippocampal sclerosis plaques or tangles could not be well characterized in this patient.
DISCUSSION
In the current study, we evaluate CSF biomarker results in a very large cohort of carefully characterized memory clinic patients with a variety of diagnoses. For the differential diagnosis of patients with AD vs patients with other types of dementia, the combination of CSF A␤42 and p-tau yields the best diagnostic accuracy. Sensitivity is high for AD, but specificity for other types of dementias is moderate. In DLB almost half of the patients fall into the category AD according to their CSF biomarker profile. Also in FTLD, VaD, and CBD, a substantial proportion of patients have a CSF AD profile. Patients with CJD and PSP can be separated from AD based on the combination of CSF biomarkers. In PSY and SMC a CSF AD profile, based on the cutoff line comparing AD with OD, is uncommon.
What could cause the overlap in CSF AD profile between the different types of dementias? First, misdiagnosis cannot be ruled out. In the present study clinical diagnosis is used as gold standard. This diagnosis is based on a large battery of investigations and on expert opinion after consensus in a multidisciplinary team. Most subjects are followed for years, increasing our confidence in baseline diagnosis. The small sample of patients with diagnosis at autopsy reveals a reasonable clinico-pathologic concordance. Moreover, there is a good concordance between CSF biomarker classification and neuropathologic diagnosis. Remarkably, the agreement between neuropathologic diagnoses vs CSF biomarker profile is in the same order of magnitude as the agreement between clinical diagnoses vs CSF biomarker profile, which strengthens our opinion that CSF biomarkers give a good reflection of the neuropathology, even in cases with clinical doubt or mixed pathology. 4, 25 A second explanation for the overlap in CSF AD profile is that mixed dementias is a common finding at autopsy. 26 Pure forms of (early onset) AD or other types of dementias are a minority in the whole spectrum of dementias. 26 -29 Our findings of overlap in CSF A␤42 and CSF (p)t-tau between the different dementias are thus not that surprising. In most studies low sensitivity and specificity figures of clinical diagnosis are found in autopsy confirmed cases. 30 Furthermore, synergistic mechanisms between major pathologic proteins (amyloid ␤, tau, ␣-synuclein, TDP-43) suggest common pathogenic mechanisms. 31 In DLB and VaD mixed pathology is often found, 28, 32 and our findings of low CSF A␤42 correspond with earlier studies. 3 In DLB AD-related pathology is found especially in patients with more severe cognitive impairment. 33 We find an association between MMSE and age with CSF A␤42 in DLB, which suggests the presence of plaques in the brain of the patients with the most severe dementia and aged patients with DLB. 34 The decrease of CSF A␤42 and increase of CSF (p)t-tau in FTLD could be due to inclusion of patients with progressive nonfluent aphasia in this group, exhibiting plaques and tangles in the brain as in AD. 27 The moderately decreased CSF levels of A␤42 and increased p-tau levels in CBD are not surprising as this type of dementia is linked with a number of pathologies, including AD pathology. 35 Decreased CSF A␤42 levels in CBD have been shown before, as well as increased CSF p-tau. 36 The increase of CSF p-tau in some of the patients with CBD could be attributed to cerebral tau depositions, either as a characteristic of CBD pathology (classified as tauopathy) or as a result of AD pathology, which is more likely as p-tau is increased in CSF and not t-tau. As far as we know, this is the largest single center sample thus far reported. This large sample size makes our data robust, especially in view of the inclusion of patients with other types of dementia. 4, 30 However, there are a few limitations to this study. First, we included patients with SMC instead of healthy controls, and consider them as the "worried well" of our memory clinic population, based on their normal clinical investigations. Our SMC population show normal CSF biomarker levels in 88%, comparable with the prevalence in a previously published population-based sample without cognitive complaints (i.e., 12% CSF AD profile). 37 We are currently performing follow-up studies to study the predictive value of CSF biomarkers in SMC. Second, our study group is relatively young. Pathology differs between young and old patients with AD, patients with dementia, and patients without dementia. 38 Our study clearly shows that patients with different types of dementia and older patients with SMC are more prone to have a CSF AD profile. In line with former studies, older individuals are more likely to have AD-like biomarkers. 16, 39 Conversely, this implies that CSF biomarkers may be most informative in younger patients, which should be taken into account for use in clinical practice. Third, we have neuropathologic data only in a small subgroup of patients, forming an unintended selection of the more complex patients. In this selected group the clinico-neuropathologic-CSF biomarker concordance is high, but prospective studies would reveal whether this is also the case in unselected patients. A recent study showed low sensitivity for DLB comparing clinical with autopsy diagnosis, especially in patients with more severe dementia. 40 Clinical diagnosis is the gold standard in the present study. To date, pathology remains the true gold standard for diagnosing the presence of biological disease, although this can also be debated, as postmortem information is by definition post hoc, mostly years after the diagnosis was first made.
Our data support the value of CSF biomarkers for confirmation of the clinical diagnosis of AD, or to exclude AD with high degree of certainty. Further studies need to focus on the discovery of more specific biomarkers as well as on comparing CSF biomarkers with autopsy to understand the overlap between different types of dementias and the heterogeneity of AD.
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